Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001104659-25-004963
Filing Date
2025-01-21
Accepted
2025-01-21 18:38:09
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 27763
  Complete submission text file 0001104659-25-004963.txt   29550
Mailing Address 7733 FORSYTH BOULEVARD ST. LOUIS MO 63105
Business Address 7733 FORSYTH BOULEVARD ST. LOUIS MO 63105 314-726-6700
RiverVest Venture Fund III, L.P. (Filed by) CIK: 0001601559 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A

Mailing Address 6707 WINCHESTER CIRCLE, SUITE 400 BOULDER CO 80301
Business Address 6707 WINCHESTER CIRCLE, SUITE 400 BOULDER CO 80301 (720) 307-2892
OnKure Therapeutics, Inc. (Subject) CIK: 0001637715 (see all company filings)

EIN.: 472309515 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-92480 | Film No.: 25543573
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)